Articles tagged with Eosinophils
Researchers at UCSF have discovered a link between meal times and daily changes in the immune system. Eosinophils, previously thought to fight parasitic diseases, may actually help invaders, according to the study. This discovery could lead to new strategies for fighting chronic parasitic infection and allergies.
Researchers have discovered that a small protein chemokine called CCL26 plays a crucial role in the development and severity of asthma. CCL26 induces a greater migration of eosinophils in asthmatic airways compared to healthy volunteers, making it a potential target for new treatments.
A Phase IIa clinical trial found that dupilumab reduced asthma exacerbations by 87% and improved lung function, morning peak expiratory flow, and asthma symptoms. The study suggests dupilumab may be an effective treatment option for patients with persistent asthma.
UCSF scientists discovered that muscle repair requires the action of two types of cells: eosinophils and fibro/adipogenic cells. Eosinophils help clear cellular debris and collaborate with FAP cells to trigger muscle regrowth.
A new test, Esophageal String Test (EST), uses a string that stretches through the esophagus to monitor eosinophilic esophagitis treatment. This non-invasive test can accurately diagnose EoE as effectively as endoscopy with biopsy, potentially reducing complications and improving patient care.
Researchers mapped eosinophil distribution in esophagus, showing current biopsies may under- or misdiagnose eosinophilic esophagitis. The study suggests new diagnostic methods could be available in five years.
Researchers found a single SNP, rs36498, associated with higher asthma susceptibility in two populations. The mutation may increase eosinophils, leading to asthma attacks. Further study is needed to understand the role of Siglec-8 gene mutations in asthma.
Researchers developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks. The treatment targets specific immune cells, showing promise as a new weapon against life-endangering conditions.
Research from the American Journal of Pathology reveals that glycosaminoglycans contribute to skeletal abnormalities in patients with lysosomal storage diseases. Additionally, αvβ3-integrin expression improves ovarian cancer patient prognosis, while CpG DNA may be a therapeutic candidate for Alzheimer's disease treatment.
A study found that male diabetics with higher eosinophil counts in their blood have a stronger link to diabetic nephropathy and increased risk of heart disease. Anti-inflammatory treatments used for allergies may also benefit male patients with diabetes.
Patients with severe asthma suffering from persistent eosinophilia show significant improvement in symptoms after receiving mepolizumab injections. The treatment reduces the need for prednisone and decreases eosinophil counts, offering new hope for managing this debilitating condition.
A large-scale genome-wide association scan found sequence variants associated with asthma, shedding light on disease mechanisms and potential biochemical pathways. The study also confirms previous findings linking the interleukin-1 gene cluster to asthma.
Researchers at Massachusetts General Hospital have developed noninvasive methods to visualize eosinophils in real-time, revealing the impact of dexamethasone on allergic airway inflammation. These techniques may improve diagnosis and treatment assessment for asthma.
Researchers at Mayo Clinic and Virginia Bioinformatics Institute discover that eosinophils exert a strong immune response against the environmental fungus Alternaria alternata. The innate immune system of humans is capable of killing the fungus, which is linked to airway inflammation, chronic rhinosinusitis, and bronchial asthma.
Researchers discovered that eosinophils release mitochondrial DNA, binding it to toxic granule proteins to form a net that traps and kills bacteria. This mechanism is linked to improved survival rates and lower bacterial numbers in mice with widespread infections.
Researchers at the University of Illinois Chicago are developing string probe tests to diagnose eosinophilic esophagitis, a condition where defense cells attack the esophagus. The test uses a swallowed string with gelatin capsule to measure inflammatory proteins and replace repeat endoscopies.
Inhibiting PIN1 has been shown to reduce airway fibrosis driven by TGF-beta-1 production in rodents with chronic asthma. Mice lacking PIN1 also exhibited reduced airway fibrosis when exposed to allergens.
Researchers have identified eosinophils as a major contributor to asthma symptoms, finding that they play a crucial role in mucous production and airway obstruction. The study suggests that targeting eosinophils could lead to the development of new treatments for asthma, which affects an estimated 17 million people in the US.
Researchers identified a specific set of genes expressed differently in individuals with eosinophilic esophagitis (EE), a chronic disease causing inflammation in the esophagus. The study found that eotaxin-3 levels were significantly higher in EE patients, suggesting potential therapeutic targets.
Researchers identified four severity classifications of chronic rhinosinusitis, including patients with polyps and high levels of eosinophils having the worst disease. The study suggests using a 'fingerprint of inflammation' obtained from a simple blood test to categorize patients and guide treatment.
Two studies published in Science suggest that eosinophils play a crucial role in the development of asthma, but the exact mechanisms are not yet clear. The findings challenge previous theories and highlight the importance of considering individual genetic factors in treating asthma.
A new study by Mayo Clinic researchers demonstrates that eosinophils are required for mucus accumulation and lung dysfunction associated with asthma. Transgenic mice without eosinophils showed reduced or eliminated disease symptoms following allergen exposure, paving the way for novel therapies to treat and prevent asthma.
Eosinophilic esophagitis (EE) is a rapidly rising disorder characterized by severely elevated levels of eosinophils in the esophagus, leading to vomiting and difficulty swallowing. The disease has a familial pattern suggesting genetic or environmental factors, warranting further study.
The calcium-sensing receptor plays a crucial role in regulating mammary gland function, influencing milk production and composition. This study demonstrates that the receptor helps match milk production with available calcium levels in the mother's body.
Researchers report success with new anti-IL-5 therapy in treating severe forms of hypereosinophilic syndrome, reducing eosinophil counts and improving symptoms. The treatment has been well-tolerated and improved the quality of life for all four patients, including one who regained ability to eat solid foods after years of inability.
Researchers identified four asthma patient subsets defined by age of onset and presence/absence of eosinophils, suggesting different biological processes and mechanisms. Early-onset asthma was associated with allergies, while late-onset asthma showed rapid lung function loss.
Researchers at Imperial College London have discovered that targeting eosinophils can disrupt airway scarring and remodelling, a process contributing to chronic asthma. The study's findings suggest a potential breakthrough for developing more effective asthma treatments.
Researchers found that a humanized anti-human interleuken antibody reduced eosinophils in severe asthma patients, improving pulmonary function. In another study, poor oral hygiene was linked to an increased risk of aspiration pneumonia, with Gram-negative bacteria being the main culprits.
Researchers found that normalizing induced sputum eosinophil count reduces asthma exacerbations by 63% and severe asthma attacks by 67%. The strategy has implications for regular monitoring of airway inflammation to treat moderate to severe asthma.
Imatinib mesylate, a drug used to treat leukemia, has shown remarkable success in reducing eosinophil levels in people with hypereosinophilic syndrome (HES), a difficult-to-treat inflammatory disease. Four of five patients studied experienced complete elimination of symptoms.